IsisCB Explore

Article ID: CBB559629478

Homo adhaerens: Risk and adherence in biomedical HIV prevention research (December 2020)

Clay Davis (Author)

Social Studies of Science
Volume: 50
Issue: 6
Pages: 860-880
Publication date: December 2020
Language: English

DOI: 10.1177/0306312720933943

URI: https://journals.sagepub.com/doi/full/10.1177/0306312720933943

Outside Links

PubMed

WorldCat

Google Scholar

JSTOR

Research methods Research Biomedicine Science and technology studies (STS) Human immunodeficiency viruses (HIV) Risk Medicine Therapeutic practice; therapy; treatment Patients Clinical trials 21st century

After the turn of the millennium, HIV clinical researchers pivoted from developing and testing new antiretrovirals (ARVs) for treatment, to reconfiguring the same molecules for pre-exposure prophylaxis (PrEP). In 2012, Truvada became the first HIV therapy to also be approved by the FDA for PrEP, regarded as a magic bullet that promised to end the epidemic. However, six years after its approval, it continues to be inaccessible to those who are most vulnerable. In this article, I critically analyze HIV PrEP clinical trials, dissecting the novel techniques researchers use to demonstrate efficacy. I argue that in making sense of the interplay between adherence to a prophylactic regimen and risk for HIV, biomedical HIV prevention research has revealed a new subject of biopolitics, Homo adhaerens. In the early 2000s, clinical researchers operating in the Global South identified Homo adhaerens as the ideal subject, one who embodies both high-risk behavior and diligent adherence to a daily oral regimen. I trace the construction of Homo adhaerens to the United States, where I listen closely to activists engaged with the ongoing DISCOVER trial of PrEP. Activists either aspire for Homo adhaerens as a standard, making the liberal argument that expanding access could make PrEP successful, or they rebuke the framework of clinical research that produces narrow understandings of adherence, efficacy, and universality. Ultimately, I argue that by failing to grapple with the social realities that underlie poor adherence, PrEP clinical trials produce knowledge that is not useful for those who are most vulnerable.

...More

Citation URI

data.isiscb.org/p/isis/citation/CBB559629478

This citation is part of the Isis database.

Citations Indexes

Similar Citations

Article Brives, Charlotte; (2013)
Identifying ontologies in a clinical trial (/p/isis/citation/CBB362744143/)

Article Petty, JuLeigh; Heimer, Carol A.; (2011)
Extending the rails: How research reshapes clinics (/p/isis/citation/CBB060848255/)

Article Arjun Devanesan; (2020)
Medical nihilism: The limits of a decontextualised critique of medicine (/p/isis/citation/CBB328328676/)

Article Martine Lappé; (October 2016)
The maternal body as environment in autism science (/p/isis/citation/CBB810340394/)

Article Jill A. Fisher; (March 2015)
Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials (/p/isis/citation/CBB066653855/)

Article Aaron T. Norton; (October 2017)
Foreskin and the molecular politics of risk (/p/isis/citation/CBB510383345/)

Article Katrin Amelang; Susanne Bauer; (August 2019)
Following the algorithm: How epidemiological risk-scores do accountability (/p/isis/citation/CBB077353059/)

Article Lisa Lindén; (July 2021)
Moving Evidence: Patients’ Groups, Biomedical Research, and Affects (/p/isis/citation/CBB080289080/)

Article Sihn, Kyu-Hwan; (2013)
The Achievements and Limitations of Researches That Make Use of Interviews for the History of Medicine in Korea (/p/isis/citation/CBB001213257/)

Book Robert Aronowitz; (2015)
Risky Medicine: Our Quest to Cure Fear and Uncertainty (/p/isis/citation/CBB544783309/)

Article Morgan Meyer; (2022)
Taking responsibility, making irresponsibility: Controversies in human gene editing (/p/isis/citation/CBB072011815/)

Article Sibille Merz; (July 2021)
Global Trials, Local Bodies: Negotiating Difference and Sameness in Indian For-profit Clinical Trials (/p/isis/citation/CBB863654493/)

Article Stephen C. Rea; Hanzelle Kleeman; Qin Zhu; Benjamin Gilbert; Chuan Yue; (2020)
Crowdsourcing as a Tool for Research: Methodological, Fair, and Political Considerations (/p/isis/citation/CBB450321760/)

Article Manuela Fernández Pinto; (2019)
Doubly disadvantaged: On the recruitment of diverse subjects for clinical trials in Latin America (/p/isis/citation/CBB362533287/)

Article Panofsky, Aaron; (February 2011)
Generating sociability to drive science: Patient advocacy organizations and genetics research (/p/isis/citation/CBB539545509/)

Article Achim Rosemann; (2019)
Alter-Standardizing Clinical Trials: The Gold Standard in the Crossfire (/p/isis/citation/CBB107905760/)

Article Kohli-Laven, Nina; Bourret, Pascale; Keating, Peter; Cambrosio, Alberto; (2011)
Cancer Clinical Trials in the Era of Genomic Signatures: Biomedical Innovation, Clinical Utility, and Regulatory-Scientific Hybrids (/p/isis/citation/CBB001034675/)

Book Hans Tao-Ming Huang; (2012)
Aizi zhili yu zaidi xingdong 愛滋治理與在地行動 [AIDS Governance and Local Actions] (/p/isis/citation/CBB533967584/)

Book Kenneth Maes; (2016)
The Lives of Community Health Workers: Local Labor and Global Health in Urban Ethiopia (/p/isis/citation/CBB528353819/)

Thesis Carpenter, Elise Audrey; (2008)
The Social Practice of HIV Drug Therapy in Botswana, 2002--2004: Experts, Bureaucrats, and Health Care Providers (/p/isis/citation/CBB001561188/)